Radiomedix, Inc.

RadioMedix, Inc. is a clinical-stage biotechnology company based in Houston, Texas. Founded in 2006, the company specializes in developing and commercializing targeted radiopharmaceuticals for cancer diagnosis, monitoring, therapy, and imaging. With a team of around 26-28 employees, RadioMedix focuses on precision nuclear medicine solutions, utilizing isotopes like Ac-225, Lu-177, Pb-212, Pb-203, and Ga-68.

The company’s mission is to enhance patient life expectancy through radiotheranostics and to advance nuclear medicine discoveries. RadioMedix offers a range of products, including generator-produced radiopharmaceuticals for diagnosis and therapy, the FDA Breakthrough Therapy Designation-recognized AlphaMedix™ for treating neuroendocrine tumors, and the SmartMedix™ automated laboratory system for synthesizing PET tracers. Additionally, RadioMedix provides contract development and manufacturing organization (CDMO) services, featuring a cGMP manufacturing suite and a molecular imaging facility for preclinical evaluations.